{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T00:35:36Z","timestamp":1794270936859,"version":"4.9.0"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"vor","delay-in-days":81,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Universit\u00e9 de Sherbrooke Cancer Research Institute"},{"name":"Centre de Recherche du CHUS"},{"name":"Universit\u00e9 de Sherbrooke Cancer Research Institute"},{"name":"Canada Research Chair on Development of Personalized Therapies for Ovarian Cancer Patients"},{"name":"Cancer and Natural Sciences and Engineering Research Council of Canad"},{"name":"Centre de Recherche Clinique du Centre Hospitalier Universitaire de Sherbrooke"},{"DOI":"10.13039\/501100000156","name":"Fonds de la Recherche du Qu\u00e9bec en Sant\u00e9","doi-asserted-by":"publisher","award":["296706"],"award-info":[{"award-number":["296706"]}],"id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000156","name":"Fonds de la Recherche du Qu\u00e9bec en Sant\u00e9","doi-asserted-by":"publisher","award":["470841"],"award-info":[{"award-number":["470841"]}],"id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000156","name":"Fonds de la Recherche du Qu\u00e9bec en Sant\u00e9","doi-asserted-by":"publisher","award":["437915"],"award-info":[{"award-number":["437915"]}],"id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Student Scholarship of the Cancer Axis"},{"name":"Centre de Recherche du CHUS"},{"name":"\u2018Bourse Hugues Allard-Chamard en rhumatologie\u2019"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, yet tumor progression remains a challenge, necessitating improved patient stratification and therapeutic strategies. Tumor growth releases neoantigens that activate adaptive immunity, promoting tertiary lymphoid structure (TLS) formation through B- and T-cell interactions. T follicular helper (Tfh) cells are key in coordinating B-cell responses and are linked to favorable outcomes. A newer subset, T peripheral helper (Tph) cells, shares functional traits with Tfh cells but differs in transcriptional and migratory profiles. Though observed in various cancers, their distribution and role in tumor immunity are not fully understood.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>To investigate this, a multiplex cyclic immunofluorescence assay was developed to detect and spatially analyze Tph cells in tumors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>This revealed three CXCL13-expressing CD4+ T-cell subsets: Tfh, Tph, and a \u2018C-C motif chemokine receptor 2 (CCR2)\u2212 Tph-like\u2019 population which, in contrast to the classically CCR2-enriched Tph phenotype described in inflamed tissues, shows markedly reduced CCR2 expression. Downregulation of CXCR5 and CCR2 near CCR2\u2212 Tph-like cells suggested a shift toward local immune residency, forming immune niches. These niches were enriched with pro-inflammatory cells, including Th1, Th17, CD4+, CD8+ T cells, and B cells. Spatial profiling showed CCR2\u2212 Tph-like cells embedded in an immunoregulatory network, marked by CD69 and inhibitory checkpoints B7-H3 and PD-L1 on surrounding cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This dual signaling suggests CCR2\u2212 Tph-like cells may modulate tumor immunity by balancing activation and suppression, with potential implications for checkpoint blockade therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/discim\/kyag007","type":"journal-article","created":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T12:39:00Z","timestamp":1774096740000},"source":"Crossref","is-referenced-by-count":4,"title":["CCR2\u2212 T peripheral helper cells as potential coordinators of local immune architecture in human cancer"],"prefix":"10.1093","volume":"5","author":[{"given":"Celia del Carmen","family":"Crespo Oliva","sequence":"first","affiliation":[{"name":"Centre de Recherche du Centre Hospitalier Universitaire de Sherbrooke (CRCHUS) , Sherbrooke, Qu\u00e9bec ,","place":["Canada"]},{"name":"Department of Medicine, Division of Rheumatology, Faculty of Medicine and Health Sciences, Cancer Research Institute, Universit\u00e9 de Sherbrooke , Sherbrooke, Qu\u00e9bec ,","place":["Canada"]},{"name":"Department of Immunology and Cell Biology, Faculty of Medicine and Health Sciences, Cancer Research Institute, Universit\u00e9 de Sherbrooke , Sherbrooke, Qu\u00e9bec ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zo\u00e9","family":"Gerber","sequence":"additional","affiliation":[{"name":"Centre de Recherche du Centre Hospitalier Universitaire de Sherbrooke (CRCHUS) , Sherbrooke, Qu\u00e9bec ,","place":["Canada"]},{"name":"Department of Immunology and Cell Biology, Faculty of Medicine and Health Sciences, Cancer Research Institute, Universit\u00e9 de Sherbrooke , Sherbrooke, Qu\u00e9bec ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Jean","sequence":"additional","affiliation":[{"name":"Centre de Recherche du Centre Hospitalier Universitaire de Sherbrooke (CRCHUS) , Sherbrooke, Qu\u00e9bec ,","place":["Canada"]},{"name":"Department of Immunology and Cell Biology, Faculty of Medicine and Health Sciences, Cancer Research Institute, Universit\u00e9 de Sherbrooke , Sherbrooke, Qu\u00e9bec ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7850-2658","authenticated-orcid":false,"given":"Hugues","family":"Allard-Chamard","sequence":"additional","affiliation":[{"name":"Centre de Recherche du Centre Hospitalier Universitaire de Sherbrooke (CRCHUS) , Sherbrooke, Qu\u00e9bec ,","place":["Canada"]},{"name":"Department of Medicine, Division of Rheumatology, Faculty of Medicine and Health Sciences, Cancer Research Institute, Universit\u00e9 de Sherbrooke , Sherbrooke, Qu\u00e9bec ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3957-5533","authenticated-orcid":false,"given":"Marilyne","family":"Labrie","sequence":"additional","affiliation":[{"name":"Centre de Recherche du Centre Hospitalier Universitaire de Sherbrooke (CRCHUS) , Sherbrooke, Qu\u00e9bec ,","place":["Canada"]},{"name":"Department of Immunology and Cell Biology, Faculty of Medicine and Health Sciences, Cancer Research Institute, Universit\u00e9 de Sherbrooke , Sherbrooke, Qu\u00e9bec ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,23]]},"reference":[{"key":"2026040806513930400_kyag007-B1","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1684\/bdc.2013.1771","article-title":"Immune-checkpoints: the new anti-cancer immunotherapies","volume":"100","author":"Ileana","year":"2013","journal-title":"Bull Cancer"},{"key":"2026040806513930400_kyag007-B2","doi-asserted-by":"crossref","first-page":"1261575","DOI":"10.3389\/fphar.2023.1261575","article-title":"Unleashing the efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma: factors, strategies, and ongoing trials","volume":"14","author":"Yu","year":"2023","journal-title":"Front Pharmacol"},{"key":"2026040806513930400_kyag007-B3","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/s41416-021-01413-x","article-title":"Cancer immunotherapy: it\u2019s time to better predict patients\u2019 response","volume":"125","author":"Pilard","year":"2021","journal-title":"Br J Cancer"},{"key":"2026040806513930400_kyag007-B4","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1053\/j.seminoncol.2015.10.002","article-title":"Immunotherapy combinations with checkpoint inhibitors in metastatic melanoma: current approaches and future directions","volume":"42","author":"Atkins","year":"2015","journal-title":"Semin Oncol"},{"key":"2026040806513930400_kyag007-B5","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41568-019-0144-6","article-title":"Tertiary lymphoid structures in the era of cancer immunotherapy","volume":"19","author":"Saut\u00e8s-Fridman","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"2026040806513930400_kyag007-B6","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/s41581-023-00706-z","article-title":"The roles of tertiary lymphoid structures in chronic diseases","volume":"19","author":"Sato","year":"2023","journal-title":"Nat Rev Nephrol"},{"key":"2026040806513930400_kyag007-B7","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/978-3-030-73119-9_3","article-title":"Tumor-associated tertiary lymphoid structures: a cancer biomarker and a target for next-generation immunotherapy","volume":"1329","author":"Dieu-Nosjean","year":"2021","journal-title":"Adv Exp Med Biol"},{"key":"2026040806513930400_kyag007-B8","doi-asserted-by":"crossref","first-page":"e489","DOI":"10.1002\/mco2.489","article-title":"Tertiary lymphoid structures in cancer: immune mechanisms and clinical implications","volume":"5","author":"Wang","year":"2024","journal-title":"MedComm (2020)"},{"key":"2026040806513930400_kyag007-B9","doi-asserted-by":"crossref","first-page":"1063711","DOI":"10.3389\/fimmu.2022.1063711","article-title":"Tertiary lymphoid structures are critical for cancer prognosis and therapeutic response","volume":"13","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"key":"2026040806513930400_kyag007-B10","doi-asserted-by":"crossref","first-page":"e157215","DOI":"10.1172\/jci.insight.157215","article-title":"CXCL13-producing CD4 + T cells accumulate in the early phase of tertiary lymphoid structures in ovarian cancer","volume":"7","author":"Ukita","year":"2022","journal-title":"JCI Insight"},{"key":"2026040806513930400_kyag007-B11","doi-asserted-by":"crossref","first-page":"e91487","DOI":"10.1172\/jci.insight.91487","article-title":"CXCL13-producing TFH cells link immune suppression and adaptive memory in human breast cancer","volume":"2","author":"Gu-Trantien","year":"2017","journal-title":"JCI Insight"},{"key":"2026040806513930400_kyag007-B12","doi-asserted-by":"crossref","first-page":"e002101","DOI":"10.1136\/jitc-2020-002101","article-title":"PD-1+CXCR5-CD4+Th-CXCL13 cell subset drives B cells into tertiary lymphoid structures of nasopharyngeal carcinoma","volume":"9","author":"Li","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026040806513930400_kyag007-B13","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.3389\/fimmu.2018.01924","article-title":"T cells that help B cells in chronically inflamed tissues","volume":"9","author":"Rao","year":"2018","journal-title":"Front Immunol"},{"key":"2026040806513930400_kyag007-B14","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/s41423-020-00529-z","article-title":"Shared and distinct roles of T peripheral helper and T follicular helper cells in human diseases","volume":"18","author":"Yoshitomi","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"2026040806513930400_kyag007-B15","doi-asserted-by":"crossref","first-page":"1145573","DOI":"10.3389\/fimmu.2023.1145573","article-title":"T peripheral helper cells in autoimmune diseases: what do we know?","volume":"14","author":"Huang","year":"2023","journal-title":"Front Immunol"},{"key":"2026040806513930400_kyag007-B16","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1016\/j.immuni.2023.08.009","article-title":"Tertiary lymphoid structures and B cells: an intratumoral immunity cycle","volume":"56","author":"Fridman","year":"2023","journal-title":"Immunity"},{"key":"2026040806513930400_kyag007-B17","doi-asserted-by":"crossref","first-page":"110325","DOI":"10.1016\/j.clim.2024.110325","article-title":"T peripheral helper (Tph) cells, a marker of immune activation in cancer and autoimmune disorders","volume":"266","author":"del Carmen Crespo Oliva","year":"2024","journal-title":"Clinical Immunology"},{"key":"2026040806513930400_kyag007-B18","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1158\/1078-0432.CCR-20-3054","article-title":"Tumor mutational burden as a predictor of immunotherapy response: is more always better?","volume":"27","author":"Strickler","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2026040806513930400_kyag007-B19","doi-asserted-by":"crossref","first-page":"5024","DOI":"10.1158\/1078-0432.CCR-16-0698","article-title":"Dynamic changes in PD-L1 expression and immune infiltrates early during treatment predict response to PD-1 blockade in melanoma","volume":"23","author":"Vilain","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2026040806513930400_kyag007-B20","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1158\/1078-0432.CCR-17-2156","article-title":"Low PD-1 expression in cytotoxic CD8 \u00fe tumor-infiltrating lymphocytes confers an immune-privileged tissue microenvironment in NSCLC with a prognostic and predictive value","volume":"24","author":"Mazzaschi","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2026040806513930400_kyag007-B21","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J Clin Invest"},{"key":"2026040806513930400_kyag007-B22","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.ccell.2021.04.014","article-title":"Conserved pan-cancer microenvironment subtypes predict response to immunotherapy","volume":"39","author":"Bagaev","year":"2021","journal-title":"Cancer Cell"},{"key":"2026040806513930400_kyag007-B23","doi-asserted-by":"crossref","first-page":"1275890","DOI":"10.3389\/fimmu.2023.1275890","article-title":"Delineating spatial cell-cell interactions in the solid tumour microenvironment through the lens of highly multiplexed imaging","volume":"14","author":"Cohn","year":"2023","journal-title":"Front Immunol"},{"key":"2026040806513930400_kyag007-B24","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.immuni.2019.04.011","article-title":"T follicular helper cell biology: a decade of discovery and diseases","volume":"50","author":"Crotty","year":"2019","journal-title":"Immunity"},{"key":"2026040806513930400_kyag007-B25","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nmeth.2869","article-title":"Highly multiplexed imaging of tumor tissues with subcellular resolution by mass cytometry","volume":"11","author":"Giesen","year":"2014","journal-title":"Nat Methods"},{"key":"2026040806513930400_kyag007-B26","doi-asserted-by":"crossref","first-page":"e31657","DOI":"10.7554\/eLife.31657","article-title":"Highly multiplexed immunofluorescence imaging of human tissues and tumors using t-CyCIF and conventional optical microscopes","volume":"7","author":"Lin","year":"2018","journal-title":"Elife"},{"key":"2026040806513930400_kyag007-B27","first-page":"209","article-title":"International agency for research on cancer 2020","volume":"419","author":"GLOBOCAN","year":"2021","journal-title":"Global Cancer Obs"},{"key":"2026040806513930400_kyag007-B28","first-page":"202","article-title":"International classification of diseases for oncology (ICD-O)","volume":"31","author":"Percy","year":"1978","journal-title":"Pathol Coll Am Pathol"},{"key":"2026040806513930400_kyag007-B29","doi-asserted-by":"crossref","first-page":"903806","DOI":"10.3389\/fonc.2022.903806","article-title":"Single-cell proteomics analysis of recurrent low-grade serous ovarian carcinoma and associated brain metastases","volume":"12","author":"Pejovic","year":"2022","journal-title":"Front Oncol"},{"key":"2026040806513930400_kyag007-B30","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nature20810","article-title":"Pathologically expanded peripheral T helper cell subset drives B cells in rheumatoid arthritis","volume":"542","author":"Rao","year":"2017","journal-title":"Nature"},{"key":"2026040806513930400_kyag007-B31","doi-asserted-by":"crossref","first-page":"e0053021","DOI":"10.1128\/JVI.00530-21","article-title":"CCR2 regulates vaccine-induced mucosal T-cell memory to influenza A virus","volume":"95","author":"Lee","year":"2021","journal-title":"J Virol"},{"key":"2026040806513930400_kyag007-B32","doi-asserted-by":"crossref","first-page":"8530","DOI":"10.3390\/ijms22168530","article-title":"Roles of CCL2-CCR2 axis in the tumor microenvironment","volume":"22","author":"Kadomoto","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2026040806513930400_kyag007-B33","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1479-5876-9-33","article-title":"In vitro migration of cytotoxic T lymphocyte derived from a colon carcinoma patient is dependent on CCL2 and CCR2","volume":"9","author":"Berencsi","year":"2011","journal-title":"J Transl Med"},{"key":"2026040806513930400_kyag007-B34","doi-asserted-by":"crossref","first-page":"430","DOI":"10.3389\/fimmu.2016.00430","article-title":"Ectopic lymphoid structures: powerhouse of autoimmunity","volume":"7","author":"Corsiero","year":"2016","journal-title":"Front Immunol"},{"key":"2026040806513930400_kyag007-B35","doi-asserted-by":"crossref","first-page":"1465516","DOI":"10.3389\/fimmu.2024.1465516","article-title":"Tertiary lymphoid structures in ovarian cancer","volume":"15","author":"Sun","year":"2024","journal-title":"Front Immunol"},{"key":"2026040806513930400_kyag007-B36","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1749-6632.2009.05133.x","article-title":"Th1 and Th17 cells","volume":"1183","author":"Damsker","year":"2010","journal-title":"Ann N Y Acad Sci"},{"key":"2026040806513930400_kyag007-B37","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s41927-020-00154-3","article-title":"A systematic review of CXCL13 as a biomarker of disease and treatment response in rheumatoid arthritis","volume":"4","author":"Bechman","year":"2020","journal-title":"BMC Rheumatol"},{"key":"2026040806513930400_kyag007-B38","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1002\/art.38173","article-title":"A distinct human CD4+ T cell subset that secretes CXCL13 in rheumatoid synovium","volume":"65","author":"Kobayashi","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2026040806513930400_kyag007-B39","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1002\/eji.201646837","article-title":"CD69: from activation marker to metabolic gatekeeper","volume":"47","author":"Cibri\u00e1n","year":"2017","journal-title":"Eur J Immunol"},{"key":"2026040806513930400_kyag007-B40","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1002\/eji.200839028","article-title":"B7-H3 is a potent inhibitor of human T-cell activation: no evidence for B7-H3 and TREML2 interaction","volume":"39","author":"Leitner","year":"2009","journal-title":"Eur J Immunol"},{"key":"2026040806513930400_kyag007-B41","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.3390\/cancers13081935","article-title":"Cd80 expression on tumor cells alters tumor microenvironment and efficacy of cancer immunotherapy by ctla-4 blockade","volume":"13","author":"Vackova","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2026040806513930400_kyag007-B42","doi-asserted-by":"crossref","first-page":"e004424","DOI":"10.1136\/jitc-2021-004424","article-title":"Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I\/II trial","volume":"10","author":"Aggarwal","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2026040806513930400_kyag007-B43","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.4049\/jimmunol.1100164","article-title":"Activated CD69+ T cells foster immune privilege by regulating IDO expression in tumor-associated macrophages","volume":"188","author":"Zhao","year":"2012","journal-title":"J Immunol"},{"key":"2026040806513930400_kyag007-B44","doi-asserted-by":"crossref","first-page":"22328","DOI":"10.1074\/jbc.M110.123299","article-title":"CD69 suppresses sphingosine 1-phosophate receptor-1 (S1P1) function through interaction with membrane helix 4","volume":"285","author":"Bankovich","year":"2010","journal-title":"J Biol Chem"},{"key":"2026040806513930400_kyag007-B45","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1158\/1078-0432.CCR-15-1849","article-title":"Reversing T-cell dysfunction and exhaustion in cancer","volume":"22","author":"Zarour","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2026040806513930400_kyag007-B46","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/j.1600-065X.2009.00771.x","article-title":"Costimulatory and coinhibitory receptors in anti-tumor immunity","volume":"229","author":"Driessens","year":"2009","journal-title":"Immunol Rev"},{"key":"2026040806513930400_kyag007-B47","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1084\/jem.20090847","article-title":"PD-L1 regulates the development, maintenance, and function of induced regulatory T cells","volume":"206","author":"Francisco","year":"2009","journal-title":"J Exp Med"}],"container-title":["Discovery Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/discovimmunology\/advance-article-pdf\/doi\/10.1093\/discim\/kyag007\/67480764\/kyag007.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/discovimmunology\/article-pdf\/5\/1\/kyag007\/67480764\/kyag007.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/discovimmunology\/article-pdf\/5\/1\/kyag007\/67480764\/kyag007.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T10:51:53Z","timestamp":1775645513000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/discovimmunology\/article\/doi\/10.1093\/discim\/kyag007\/8537354"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2,7]]}},"URL":"https:\/\/doi.org\/10.1093\/discim\/kyag007","relation":{},"ISSN":["2754-2483"],"issn-type":[{"value":"2754-2483","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026]]},"published":{"date-parts":[[2026]]},"article-number":"kyag007"}}